<code id='2B5CEA8AB6'></code><style id='2B5CEA8AB6'></style>
    • <acronym id='2B5CEA8AB6'></acronym>
      <center id='2B5CEA8AB6'><center id='2B5CEA8AB6'><tfoot id='2B5CEA8AB6'></tfoot></center><abbr id='2B5CEA8AB6'><dir id='2B5CEA8AB6'><tfoot id='2B5CEA8AB6'></tfoot><noframes id='2B5CEA8AB6'>

    • <optgroup id='2B5CEA8AB6'><strike id='2B5CEA8AB6'><sup id='2B5CEA8AB6'></sup></strike><code id='2B5CEA8AB6'></code></optgroup>
        1. <b id='2B5CEA8AB6'><label id='2B5CEA8AB6'><select id='2B5CEA8AB6'><dt id='2B5CEA8AB6'><span id='2B5CEA8AB6'></span></dt></select></label></b><u id='2B5CEA8AB6'></u>
          <i id='2B5CEA8AB6'><strike id='2B5CEA8AB6'><tt id='2B5CEA8AB6'><pre id='2B5CEA8AB6'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:968
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          A Q&A with the global head of Boehringer Ingelheim's innovation unit
          A Q&A with the global head of Boehringer Ingelheim's innovation unit

          MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr

          read more
          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more

          UnitedHealth’s Optum accused of antitrust violations in California

          EmanateHealthsuedUnitedHealth'sOptum,allegingtheinsurerpushedittoagreenottocompeteforprimarycarephys